Core Viewpoint - Several A-share companies are set to remove their delisting risk warnings, indicating improvements in their financial health and operational focus [2][8][11]. Group 1: Company Announcements - *ST农尚 will have its delisting risk warning removed and will change its name to "农尚环境" effective May 23, 2025, after a one-day suspension on May 22 [2][8]. - *ST金时 will also remove its delisting risk warning and change its name to "金时科技" effective May 23, 2025, following a one-day suspension on May 22 [10][11]. - ST世龙 will remove its other risk warning and change its name to "世龙实业" effective May 22, 2025, after a one-day suspension on May 21 [4][6]. Group 2: Financial Performance and Compliance - ST世龙 reported that its financial statements for 2019 and 2020 contained false records, leading to administrative penalties, but has since corrected these errors and received a standard unqualified audit report for 2024 [5][6]. - *ST农尚's 2024 revenue was reported at 2.18 billion, with a net asset value of 5.24 billion, allowing it to meet the conditions for removing the delisting risk warning [9]. - *ST金时's 2024 financials showed a total profit of 349.33 million, but a net loss of 1.62 billion, with a revenue of 370 million, prompting strategic asset restructuring to enhance operational capacity [12][13].

Group 1: Company Performance and Strategies - The company plans to increase R&D investment to enhance product market share and revenue [1][3][6] - Expansion of entrusted business to improve revenue generation capabilities [1][3][6] - Optimization of operational processes to reduce operating costs and enhance profitability [1][3][6] - Streamlining organizational structure to improve operational efficiency and control labor costs [1][3][6] - Expansion of export activities to create new profit growth points [1][3][6] Group 2: Risk Management and Future Plans - The company is actively taking measures to mitigate delisting risks, including adapting to new healthcare policies and participating in procurement [6][9] - Focus on maintaining existing customer orders in the peptide business while expanding customer channels [7][9] - Commitment to advancing the approval of products under review and engaging in international business development activities [7][9] - Emphasis on cost control measures to enhance efficiency and reduce waste [7][9] Group 3: Acquisition and Restructuring - The company currently has no acquisition plans, and all relevant information will be disclosed through designated media [2][4][8] - Suggestions from investors regarding restructuring and acquisitions have been acknowledged, but no concrete plans are in place [2][3][4][8]